SCHEMBL5676263

SCHEMBL5676263

c1csc(C2COCCN2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
PRKACA P17612 1/20 0.36
PRKACG P22612 1/20 0.36
PRKACB P22694 1/20 0.36
KDM4E B2RXH2 5/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 4/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
DRD3 P35462 1/20 0.33
NOS2 P35228 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
HTR2A P28223 3/20 0.32
HTR2C P28335 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22589075 1.00 ALDH1A1 (0.38) ALDH1A1MEN1KMT2APRKACAPRKACG
SCHEMBL5677950 1.00 ALDH1A1 (0.38) ALDH1A1MEN1KMT2APRKACAPRKACG
SCHEMBL166764 0.74 CHRM5 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL20292058 0.74 CHRM5 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL6179170 0.74 CHRM5 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL5802520 0.73 ALDH1A1 (0.37) ALDH1A1MEN1KMT2AKDM4ETSHR
SCHEMBL7008410 0.73 MEN1 (0.46) ALDH1A1MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL9786152 0.73 ALDH1A1 (0.37) ALDH1A1MEN1KMT2AKDM4ETSHR
SCHEMBL4599754 0.71 MEN1 (0.45) ALDH1A1MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL6910639 0.71 DRD3 (0.41) ALDH1A1MEN1KMT2AKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 EP disclosed
US-12497395-B2 Small molecule bromodomain inhibitors and uses therof CONVERGENE, LLC 2025-12-16 US disclosed
WO-2024261329-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 WO disclosed
WO-2024261327-A1 2-(HETEROARYL-THIO)-1-(HETEROARYL)ETHANONE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 WO disclosed
EP-4424379-A2 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2024-09-04 EP disclosed
EP-3958867-B1 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2024-06-26 EP disclosed
US-20220259200-A1 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEROF CONVERGENE, LLC 2022-08-18 US disclosed
CN-114786675-A Small molecule bromodomain inhibitors and uses thereof 康威基内有限公司 2022-07-22 CN disclosed
EP-3958867-A1 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2022-03-02 EP disclosed
WO-2020219168-A1 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE, LLC (US) 2020-10-29 WO disclosed
US-20020022647-A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives BARRETT STEPHEN DOUGLAS (US) 2002-02-21 US disclosed
US-6310060-B1 FOR USE AS ANTIPROLIFERATIVE AGENT FOR USE AGAINST CANCER, PSORIASIS, RESTENOSIS, AUTOIMMUNE DISEASE, OR ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2001-10-30 US disclosed
WO-2001072711-A1 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS WYETH (US) 2001-10-04 WO disclosed
WO-2001005392-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-01-25 WO disclosed
EP-0993437-A1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-04-19 EP disclosed
WO-1999001421-A1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-01-14 WO disclosed
US-5852006-A N-aminoalkyl-substituted nitrogen-containing six membered heterocyclic compounds NIPPON CHEMIPHAR CO., LTD. (JP) 1998-12-22 US disclosed
US-5574030-A INHIBITING URINARY CONTRACTION, HETEROCYCLIC DIAMINES NIPPON CHEMIPHAR CO., LTD. (JP) 1996-11-12 US disclosed
US-5475132-A Fungicide intermediates RHONE-POULENC AGROCHIMIE (FR) 1995-12-12 US disclosed
US-5342835-A Antifungal agents based on amides containing a phenyl group RHONE-POULENC AGROCHIMIE (FR) 1994-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497395-B2 Small molecule bromodomain inhibitors and uses therof BRD4, BRPF3, BICRA ALDH1A1 4409/4885MEN1 3075/4885KMT2A 770/4885
US-20220259200-A1 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEROF BRPF3, BRDT, BRD3 ALDH1A1 4567/4885MEN1 1820/4885KMT2A 1049/4885
US-20020022647-A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives BCOR, BCL6, CBR1 ALDH1A1 1267/4885MEN1 4401/4885KMT2A 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.